{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:52:37Z","timestamp":1789584757558,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gene fusion events have been linked to oncogenesis in many cancers. However, gene fusions in meningioma are understudied compared to somatic mutations, chromosomal gains\/losses, and epigenetic changes. Fusions involving B-raf proto-oncogene, serine\/threonine kinase (<jats:italic>BRAF<\/jats:italic>) are subtypes of oncogenic <jats:italic>BRAF<\/jats:italic> genetic abnormalities that have been reported in certain cases of brain tumors, such as pilocytic astrocytomas. However, <jats:italic>BRAF<\/jats:italic> fusions have not been recognized in meningioma. We present the case of an adult female presenting with episodic partial seizures characterized by d\u00e9j\u00e0 vu, confusion, and cognitive changes. Brain imaging revealed a cavernous sinus and sphenoid wing mass and she underwent resection. Histopathology revealed a World Health Organization (WHO) grade 1 meningioma. Genetic profiling with next generation sequencing and microarray analysis revealed an in-frame <jats:italic>BRAF::PTPRN2<\/jats:italic> fusion affecting the BRAF kinase domain as well as chromothripsis of chromosome 7q resulting in multiple segmental gains and losses including amplifications of cyclin dependent kinase 6 (<jats:italic>CDK6<\/jats:italic>), tyrosine protein-kinase Met (<jats:italic>MET<\/jats:italic>), and smoothened (<jats:italic>SMO<\/jats:italic>). Elevated pERK staining in tumor cells provided evidence of activated mitogen-activated protein kinase (<jats:italic>MAPK<\/jats:italic>) signaling. This report raises the possibility that gene fusion events may be involved in meningioma pathogenesis and warrant further investigation.<\/jats:p>","DOI":"10.1186\/s40478-023-01668-w","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T12:02:29Z","timestamp":1702036949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A novel BRAF::PTPRN2 fusion in meningioma: a case report"],"prefix":"10.1186","volume":"11","author":[{"given":"Nishanth S.","family":"Sadagopan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khizar R.","family":"Nandoliya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Youngblood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"Horbinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared T.","family":"Ahrendsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-7835","authenticated-orcid":false,"given":"Stephen T.","family":"Magill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"1668_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C et al (2022) CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2015\u20132019. Neuro-Oncol 24:v1\u201395. https:\/\/doi.org\/10.1093\/neuonc\/noac202","journal-title":"Neuro-Oncol"},{"key":"1668_CR2","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1136\/jnnp.2007.121582","volume":"79","author":"S-Y Yang","year":"2008","unstructured":"Yang S-Y, Park C-K, Park S-H, Kim DG, Chung YS, Jung H-W (2008) Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 79:574\u2013580. https:\/\/doi.org\/10.1136\/jnnp.2007.121582","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1668_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/nan.12397","volume":"44","author":"F Sahm","year":"2018","unstructured":"Sahm F, Reuss DE, Giannini C (2018) WHO 2016 classification: changes and advancements in the diagnosis of miscellaneous primary CNS tumours. Neuropathol Appl Neurobiol 44:163\u2013171. https:\/\/doi.org\/10.1111\/nan.12397","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1668_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00701-012-1611-y","volume":"155","author":"JF Cornelius","year":"2013","unstructured":"Cornelius JF, Slotty PJ, Steiger HJ, H\u00e4nggi D, Polivka M, George B (2013) Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases. Acta Neurochir (Wien) 155:407\u2013413. https:\/\/doi.org\/10.1007\/s00701-012-1611-y","journal-title":"Acta Neurochir (Wien)"},{"key":"1668_CR5","doi-asserted-by":"publisher","first-page":"CNS72","DOI":"10.2217\/cns-2021-0003","volume":"10","author":"I Maggio","year":"2021","unstructured":"Maggio I, Franceschi E, Tosoni A, Nunno VD, Gatto L, Lodi R et al (2021) Meningioma: not always a benign Tumor. A review of advances in the treatment of meningiomas. CNS Oncol 10:CNS72. https:\/\/doi.org\/10.2217\/cns-2021-0003","journal-title":"CNS Oncol"},{"key":"1668_CR6","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S1470-2045(16)30321-7","volume":"17","author":"R Goldbrunner","year":"2016","unstructured":"Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E et al (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17:e383\u2013391. https:\/\/doi.org\/10.1016\/S1470-2045(16)30321-7","journal-title":"Lancet Oncol"},{"key":"1668_CR7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.14670\/HH-18-195","volume":"35","author":"F Pepe","year":"2020","unstructured":"Pepe F, Pisapia P, Del Basso de Caro ML, Conticelli F, Malapelle U, Troncone G et al (2020) Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment. Histol Histopathol 35:741\u2013749. https:\/\/doi.org\/10.14670\/HH-18-195","journal-title":"Histol Histopathol"},{"key":"1668_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"F Nassiri","year":"2021","unstructured":"Nassiri F, Liu J, Patil V, Mamatjan Y, Wang JZ, Hugh-White R et al (2021) A clinically applicable integrative molecular classification of meningiomas. Nature 597:119\u2013125. https:\/\/doi.org\/10.1038\/s41586-021-03850-3","journal-title":"Nature"},{"key":"1668_CR9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S et al (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18:682\u2013694. https:\/\/doi.org\/10.1016\/S1470-2045(17)30155-9","journal-title":"Lancet Oncol"},{"key":"1668_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/neuonc\/noaa226","volume":"23","author":"MW Youngblood","year":"2021","unstructured":"Youngblood MW, Miyagishima DF, Jin L, Gupte T, Li C, Duran D et al (2021) Associations of meningioma molecular subgroup and Tumor recurrence. Neuro-Oncol 23:783\u2013794. https:\/\/doi.org\/10.1093\/neuonc\/noaa226","journal-title":"Neuro-Oncol"},{"key":"1668_CR11","doi-asserted-by":"publisher","first-page":"21715","DOI":"10.1073\/pnas.1912858116","volume":"116","author":"AJ Patel","year":"2019","unstructured":"Patel AJ, Wan Y-W, Al-Ouran R, Revelli J-P, Cardenas MF, Oneissi M et al (2019) Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. Proc Natl Acad Sci U S A 116:21715\u201321726. https:\/\/doi.org\/10.1073\/pnas.1912858116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1668_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","volume":"54","author":"A Choudhury","year":"2022","unstructured":"Choudhury A, Magill ST, Eaton CD, Prager BC, Chen WC, Cady MA et al (2022) Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54:649\u2013659. https:\/\/doi.org\/10.1038\/s41588-022-01061-8","journal-title":"Nat Genet"},{"key":"1668_CR13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/neuonc\/noab213","volume":"24","author":"J Driver","year":"2022","unstructured":"Driver J, Hoffman SE, Tavakol S, Woodward E, Maury EA, Bhave V et al (2022) A molecularly integrated grade for meningioma. Neuro-Oncol 24:796\u2013808. https:\/\/doi.org\/10.1093\/neuonc\/noab213","journal-title":"Neuro-Oncol"},{"key":"1668_CR14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/neuonc\/noac224","volume":"25","author":"A Choudhury","year":"2023","unstructured":"Choudhury A, Chen WC, Lucas C-HG, Bayley JC, Harmanci AS, Maas SLN et al (2023) Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro-Oncol 25:520\u2013530. https:\/\/doi.org\/10.1093\/neuonc\/noac224","journal-title":"Neuro-Oncol"},{"key":"1668_CR15","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2663611\/v1","author":"D Raleigh","year":"2023","unstructured":"Raleigh D, Chen W, Choudhury A, Youngblood M, Polley M-Y, Lucas C-H et al (2023) Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-2663611\/v1. rs.3.rs-2663611","journal-title":"Res Sq"},{"key":"1668_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng.2526","volume":"45","author":"PK Brastianos","year":"2013","unstructured":"Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G et al (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285\u2013289. https:\/\/doi.org\/10.1038\/ng.2526","journal-title":"Nat Genet"},{"key":"1668_CR17","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, \u00d6zduman K et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077\u20131080. https:\/\/doi.org\/10.1126\/science.1233009","journal-title":"Science"},{"key":"1668_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ng.2552","volume":"45","author":"MJ Smith","year":"2013","unstructured":"Smith MJ, O\u2019Sullivan J, Bhaskar SS, Hadfield KD, Poke G, Caird J et al (2013) Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet 45:295\u2013298. https:\/\/doi.org\/10.1038\/ng.2552","journal-title":"Nat Genet"},{"key":"1668_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/363515a0","volume":"363","author":"GA Rouleau","year":"1993","unstructured":"Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C et al (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515\u2013521. https:\/\/doi.org\/10.1038\/363515a0","journal-title":"Nature"},{"key":"1668_CR20","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ng.3651","volume":"48","author":"VE Clark","year":"2016","unstructured":"Clark VE, Harmanc\u0131 AS, Bai H, Youngblood MW, Lee TI, Baranoski JF et al (2016) Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 48:1253\u20131259. https:\/\/doi.org\/10.1038\/ng.3651","journal-title":"Nat Genet"},{"key":"1668_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/neuros\/nyab209","volume":"90","author":"WL Bi","year":"2022","unstructured":"Bi WL, Santagata S (2022) Skull Base tumors: Neuropathology and Clinical implications. Neurosurgery 90:243. https:\/\/doi.org\/10.1093\/neuros\/nyab209","journal-title":"Neurosurgery"},{"key":"1668_CR22","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3892\/ol.2014.2042","volume":"7","author":"M Bujko","year":"2014","unstructured":"Bujko M, Kober P, Tysarowski A, Matyja E, Mandat T, Bonicki W et al (2014) EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas. Oncol Lett 7:2019\u20132022. https:\/\/doi.org\/10.3892\/ol.2014.2042","journal-title":"Oncol Lett"},{"key":"1668_CR23","unstructured":"Alliance for Clinical Trials in Oncology (2023) Phase II trial of SMO\/ AKT\/ NF2\/CDK inhibitors in Progressive Meningiomas with SMO\/ AKT\/ NF2\/CDK pathway mutations. clinicaltrials.gov"},{"key":"1668_CR24","doi-asserted-by":"publisher","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","volume":"108","author":"F Sahm","year":"2015","unstructured":"Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J et al (2015) TERT promoter mutations and risk of recurrence in Meningioma. JNCI J Natl Cancer Inst 108:djv377. https:\/\/doi.org\/10.1093\/jnci\/djv377","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1668_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00401-023-02571-3","volume":"146","author":"JZ Wang","year":"2023","unstructured":"Wang JZ, Patil V, Liu J, Dogan H, Tabatabai G, Yefet LS et al (2023) Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas. Acta Neuropathol (Berl) 146:145\u2013162. https:\/\/doi.org\/10.1007\/s00401-023-02571-3","journal-title":"Acta Neuropathol (Berl)"},{"key":"1668_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/WCO.0000000000001002","volume":"34","author":"T Graillon","year":"2021","unstructured":"Graillon T, Tabouret E, Chinot O (2021) Chemotherapy and targeted therapies for meningiomas: what is the evidence? Curr Opin Neurol 34:857. https:\/\/doi.org\/10.1097\/WCO.0000000000001002","journal-title":"Curr Opin Neurol"},{"key":"1668_CR27","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","volume":"37","author":"M Dankner","year":"2018","unstructured":"Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR (2018) Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene 37:3183\u20133199. https:\/\/doi.org\/10.1038\/s41388-018-0171-x","journal-title":"Oncogene"},{"key":"1668_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/1477-3163.126759","volume":"13","author":"A Jarkowski","year":"2014","unstructured":"Jarkowski A, Khushalani NI (2014) BRAF and beyond: tailoring strategies for the individual Melanoma patient. J Carcinog 13:1. https:\/\/doi.org\/10.4103\/1477-3163.126759","journal-title":"J Carcinog"},{"key":"1668_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954. https:\/\/doi.org\/10.1038\/nature00766","journal-title":"Nature"},{"key":"1668_CR30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/1947601911407323","volume":"2","author":"D Matallanas","year":"2011","unstructured":"Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A et al (2011) Raf family kinases: old dogs have learned new tricks. Genes Cancer 2:232\u2013260. https:\/\/doi.org\/10.1177\/1947601911407323","journal-title":"Genes Cancer"},{"key":"1668_CR31","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.2147\/CMAR.S170105","volume":"10","author":"J-H Pan","year":"2018","unstructured":"Pan J-H, Zhou H, Zhu S-B, Huang J-L, Zhao X-X, Ding H et al (2018) Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant Colorectal cancer. Cancer Manag Res 10:2289\u20132301. https:\/\/doi.org\/10.2147\/CMAR.S170105","journal-title":"Cancer Manag Res"},{"key":"1668_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ctrv.2018.04.006","volume":"66","author":"A Leonetti","year":"2018","unstructured":"Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L et al (2018) BRAF in non-small cell Lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev 66:82\u201394. https:\/\/doi.org\/10.1016\/j.ctrv.2018.04.006","journal-title":"Cancer Treat Rev"},{"key":"1668_CR33","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1210\/jc.2003-030305","volume":"88","author":"H Namba","year":"2003","unstructured":"Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI et al (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393\u20134397. https:\/\/doi.org\/10.1210\/jc.2003-030305","journal-title":"J Clin Endocrinol Metab"},{"key":"1668_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","volume":"121","author":"G Schindler","year":"2011","unstructured":"Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (Berl) 121:397\u2013405. https:\/\/doi.org\/10.1007\/s00401-011-0802-6","journal-title":"Acta Neuropathol (Berl)"},{"key":"1668_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13000-016-0506-2","volume":"11","author":"F Behling","year":"2016","unstructured":"Behling F, Barrantes-Freer A, Skardelly M, Nieser M, Christians A, Stockhammer F et al (2016) Frequency of BRAF V600E mutations in 969 central nervous system Neoplasms. Diagn Pathol 11:55. https:\/\/doi.org\/10.1186\/s13000-016-0506-2","journal-title":"Diagn Pathol"},{"key":"1668_CR36","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in Melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516. https:\/\/doi.org\/10.1056\/NEJMoa1103782","journal-title":"N Engl J Med"},{"key":"1668_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic Melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet Lond Engl 380:358\u2013365. https:\/\/doi.org\/10.1016\/S0140-6736(12)60868-X","journal-title":"Lancet Lond Engl"},{"key":"1668_CR38","doi-asserted-by":"publisher","first-page":"7595","DOI":"10.1158\/1078-0432.ccr-11-1456","volume":"17","author":"TP Nicolaides","year":"2011","unstructured":"Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K et al (2011) Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 17:7595\u20137604. https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-1456","journal-title":"Clin Cancer Res"},{"key":"1668_CR39","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/pbc.24891","volume":"61","author":"F Bautista","year":"2014","unstructured":"Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L et al (2014) Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer 61:1101\u20131103. https:\/\/doi.org\/10.1002\/pbc.24891","journal-title":"Pediatr Blood Cancer"},{"key":"1668_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/cns.15.40","volume":"5","author":"MC Chamberlain","year":"2016","unstructured":"Chamberlain MC (2016) Recurrent ganglioglioma in adults treated with BRAF inhibitors. CNS Oncol 5:27\u201329. https:\/\/doi.org\/10.2217\/cns.15.40","journal-title":"CNS Oncol"},{"key":"1668_CR41","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3109\/0284186X.2015.1021428","volume":"55","author":"S Hofer","year":"2016","unstructured":"Hofer S, Berthod G, Riklin C, Rushing E, Feilchenfeldt J (2016) BRAF V600E mutation: a treatable driver mutation in pleomorphic xanthoastrocytoma (PXA). Acta Oncol Stockh Swed 55:122\u2013123. https:\/\/doi.org\/10.3109\/0284186X.2015.1021428","journal-title":"Acta Oncol Stockh Swed"},{"key":"1668_CR42","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00381-019-04282-1","volume":"35","author":"H Kurani","year":"2019","unstructured":"Kurani H, Gurav M, Shetty O, Chinnaswamy G, Moiyadi A, Gupta T et al (2019) Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups. Childs Nerv Syst ChNS off J Int Soc Pediatr Neurosurg 35:1525\u20131536. https:\/\/doi.org\/10.1007\/s00381-019-04282-1","journal-title":"Childs Nerv Syst ChNS off J Int Soc Pediatr Neurosurg"},{"key":"1668_CR43","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/NEN.0000000000000226","volume":"74","author":"C Faulkner","year":"2015","unstructured":"Faulkner C, Ellis HP, Shaw A, Penman C, Palmer A, Wragg C et al (2015) BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15 \u2013 9 fusions are more frequent in the Midline Than within the Cerebellum. J Neuropathol Exp Neurol 74:867\u2013872. https:\/\/doi.org\/10.1097\/NEN.0000000000000226","journal-title":"J Neuropathol Exp Neurol"},{"key":"1668_CR44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s40478-021-01248-w","volume":"9","author":"N Manoharan","year":"2021","unstructured":"Manoharan N, Ajuyah P, Senapati A, Wong M, Mullins A, Rodriguez M et al (2021) Diffuse leptomeningeal glioneuronal tumour (DLGNT) in children: the emerging role of genomic analysis. Acta Neuropathol Commun 9:147. https:\/\/doi.org\/10.1186\/s40478-021-01248-w","journal-title":"Acta Neuropathol Commun"},{"key":"1668_CR45","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00401-015-1410-7","volume":"129","author":"VP Collins","year":"2015","unstructured":"Collins VP, Jones DTW, Giannini C (2015) Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol (Berl) 129:775\u2013788. https:\/\/doi.org\/10.1007\/s00401-015-1410-7","journal-title":"Acta Neuropathol (Berl)"},{"key":"1668_CR46","first-page":"429","volume":"109","author":"Q Li","year":"1997","unstructured":"Li Q, Borovitskaya AE, DeSilva MG, Wasserfall C, Maclaren NK, Notkins AL et al (1997) Autoantigens in insulin-dependent Diabetes Mellitus: molecular cloning and characterization of human IA-2 beta. Proc Assoc Am Physicians 109:429\u2013439","journal-title":"Proc Assoc Am Physicians"},{"key":"1668_CR47","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1038\/s41598-019-40486-w","volume":"9","author":"S Lee","year":"2019","unstructured":"Lee S (2019) The association of genetically controlled CpG methylation (cg158269415) of protein tyrosine phosphatase, receptor type N2 (PTPRN2) with childhood obesity. Sci Rep 9:4855. https:\/\/doi.org\/10.1038\/s41598-019-40486-w","journal-title":"Sci Rep"},{"key":"1668_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.15252\/embj.201591973","volume":"35","author":"CA Sengelaub","year":"2016","unstructured":"Sengelaub CA, Navrazhina K, Ross JB, Halberg N, Tavazoie SF (2016) PTPRN2 and PLC\u03b21 promote metastatic Breast cancer cell migration through PI(4,5)P2-dependent actin remodeling. EMBO J 35:62\u201376. https:\/\/doi.org\/10.15252\/embj.201591973","journal-title":"EMBO J"},{"key":"1668_CR49","doi-asserted-by":"publisher","first-page":"41890","DOI":"10.18632\/oncotarget.17462","volume":"8","author":"D Gentilini","year":"2017","unstructured":"Gentilini D, Scala S, Gaudenzi G, Garagnani P, Capri M, Cescon M et al (2017) Epigenome-wide association study in hepatocellular carcinoma: identification of stochastic epigenetic mutations through an innovative statistical approach. Oncotarget 8:41890\u201341902. https:\/\/doi.org\/10.18632\/oncotarget.17462","journal-title":"Oncotarget"},{"key":"1668_CR50","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jgg.2015.06.003","volume":"42","author":"E-J Lee","year":"2015","unstructured":"Lee E-J, Rath P, Liu J, Ryu D, Pei L, Noonepalle SK et al (2015) Identification of global DNA methylation signatures in Glioblastoma-Derived Cancer Stem cells. J Genet Genomics Yi Chuan Xue Bao 42:355\u2013371. https:\/\/doi.org\/10.1016\/j.jgg.2015.06.003","journal-title":"J Genet Genomics Yi Chuan Xue Bao"},{"key":"1668_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","volume":"144","author":"PJ Stephens","year":"2011","unstructured":"Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ et al (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144:27\u201340. https:\/\/doi.org\/10.1016\/j.cell.2010.11.055","journal-title":"Cell"},{"key":"1668_CR52","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/cells10051102","volume":"10","author":"M Shorokhova","year":"2021","unstructured":"Shorokhova M, Nikolsky N, Grinchuk T (2021) Chromothripsis\u2014Explosion in Genetic Science Cells 10:1102. https:\/\/doi.org\/10.3390\/cells10051102","journal-title":"Chromothripsis\u2014Explosion in Genetic Science Cells"},{"key":"1668_CR53","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.wneu.2019.07.003","volume":"130","author":"C Baltus","year":"2019","unstructured":"Baltus C, Toffoli S, London F, Delr\u00e9e P, Gilliard C, Gustin T (2019) Chromothripsis in an early recurrent Chordoid Meningioma. World Neurosurg 130:380\u2013385. https:\/\/doi.org\/10.1016\/j.wneu.2019.07.003","journal-title":"World Neurosurg"},{"key":"1668_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41525-017-0014-7","volume":"2","author":"WL Bi","year":"2017","unstructured":"Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK et al (2017) Genomic landscape of high-grade meningiomas. NPJ Genomic Med 2:15. https:\/\/doi.org\/10.1038\/s41525-017-0014-7","journal-title":"NPJ Genomic Med"},{"key":"1668_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cell.2012.01.006","volume":"148","author":"CA Maher","year":"2012","unstructured":"Maher CA, Wilson RK (2012) Chromothripsis and human Disease: piecing together the shattering process. Cell 148:29\u201332. https:\/\/doi.org\/10.1016\/j.cell.2012.01.006","journal-title":"Cell"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01668-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-023-01668-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01668-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T12:05:27Z","timestamp":1702037127000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-023-01668-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1668"],"URL":"https:\/\/doi.org\/10.1186\/s40478-023-01668-w","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"5 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no disclosures of relevance to this work. S.T.M. is supported by the Malnati Brain Tumor Institute of the Lurie Cancer Center.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This study was approved by our Institutional Review Board and patient gave consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent regarding the submission and potential publication of this manuscript was obtained from the case study patient. Consent for treatment and surgery was obtained during the patient\u2019s hospitalization.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}